MedPath

Liver Injury by Statins in Patients With History of Hepatitis B Virus Infection

Conditions
Hepatitis B Virus Infection History
Liver Injury
Registration Number
NCT02808299
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Brief Summary

The purpose of this study is to investigate the incidence of liver injury by statins in coronary heart disease (CHD) patients with history of hepatitis B virus (HBV) infection.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
600
Inclusion Criteria
  • patients with CHD receive long-term statin treatment
Exclusion Criteria
  • ALT is over ULN at baseline
  • infection of Hepatitis A Virus, Hepatitis C Virus or Hepatitis E Virus
  • triglyceride is over 4.5 mmol/L
  • decompensated liver cirrhosis (Child B or C)
  • active stage of HBV
  • infection of Burkitt's lymphoma virus or cytomegalovirus, or other acute infectious disease
  • congestive heart failure
  • malignant tumor
  • autoimmune disease
  • receive other potential hepatotoxicity drugs such as immunosuppressant, antituberculotic and non-steroid anti-inflammatory drug.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
changes of alanine transaminase (ALT, U/L)one month, three months, six months

The peak increases of ALT from baseline to follow-up

number of participants with alanine transaminase (ALT) increasing over 3 folds of upper limit normally (ULN)one month, three months, six months
Secondary Outcome Measures
NameTimeMethod
number of participants with alanine transaminase (ALT) increasing over the ULNone month, three months, six months

Trial Locations

Locations (1)

First Affiliated Hospital of Nanjing Medical University

🇨🇳

Nanjing, Jiangsu, China

First Affiliated Hospital of Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.